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Background: The absolute and relative importance of smoking to vascular and nonvascular outcomes in
people with chronic kidney disease (CKD), as well its relevance to kidney disease progression, is uncertain.
Study Design: Observational study.
Setting & Participants: 9,270 participants with CKD enrolled in SHARP.
Predictor: Baseline smoking status (current, former, and never).
Outcomes: Vascular events, site-specific cancer, ESRD, rate of change in estimated glomerular filtration
rate (eGFR), and cause-specific mortality.
Results: At baseline, 1,243 (13%) participants were current smokers (median consumption, 10 cigarettes/
day); 3,272 (35%), former smokers; and 4,755 (51%), never smokers. Median follow-up was 4.9 years. Vascular
event rates were 36% higher for current than never smokers (2,317 events; relative risk [RR], 1.36; 95% CI,
1.19-1.55), reflecting increases in both atherosclerotic (RR, 1.49; 95% CI, 1.26-1.76) and nonatherosclerotic
(RR, 1.25; 95% CI, 1.05-1.50) events. Cancer was 37% higher among current smokers (632 events; RR,
1.37; 95% CI, 1.07-1.76), with the biggest RRs for lung (RR, 9.31; 95% CI, 4.37-19.83) and upper
aerodigestive tract (RR, 4.87; 95% CI, 2.10-11.32) cancers. For 6,245 patients not receiving dialysis at
baseline, ESRD incidence did not differ significantly between current and never smokers (2,141 events; RR,
1.02; 95% CI, 0.89-1.17), nor did estimated rate of change in eGFR (current smokers, 21.77 6 0.14 [SE];
never smokers, 21.70 6 0.07 mL/min/1.73 m2 per year). All-cause mortality was 48% higher among current
smokers (2,257 events; RR, 1.48; 95% CI, 1.30-1.70), with significant increases in vascular (RR, 1.35; 95%
CI, 1.07-1.69) and nonvascular (RR, 1.60; 95% CI, 1.34-1.91) causes of death, especially cancer (RR, 2.32;
95% CI, 1.58-3.40) and respiratory (RR, 2.25; 95% CI, 1.51-3.35) mortality.
Limitations: Smoking status not assessed during follow-up.
Conclusions: In this study of patients with CKD, smoking significantly increased the risks for vascular and
nonvascular morbidity and mortality, but was not associated with kidney disease progression. The associa-
tions with vascular and neoplastic disease are in keeping with those observed in the general population and
are likely modifiable by cessation.
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Staplin et alEditorial, p. 338n 2010, it was estimated that smoking tobaccoI resulted in about 4.5 million male and 2 million
female deaths globally.1 Smoking was the leading
global cause of disability in men and fourth most
important cause in women and was ranked in the top
5 causes of disease and death in every region of
the world except for parts of sub-Saharan Africa.1
Smoking tobacco increases the risks for a wide
range of chronic conditions, including cancer,2-5
cardiovascular diseases2-5 (coronary heart disease,
stroke, and heart failure), respiratory diseases,2-4 and
chronic kidney disease (CKD).5,6
Patients with CKD have substantially elevated risks
for cancer,7 cardiovascular disease,8 and progressive
loss of kidney function9; therefore, smoking might be
expected to be particularly hazardous for such patients.
However, few epidemiologic studies have examined
the effects of smoking directly in populations of pa-
tients with CKD. In the largest previous study (in
which 3,941 dialysis patients were followed up for a
mean of 2.2 years), current smokers had a 59%
increased risk for new heart failure and 37% increased
risk for death when compared with never smokers,10
but there was no signiﬁcant excess risk for ischemic
heart disease or cerebrovascular disease (albeit based
on only 232 and 64 events, respectively).10
The Study of Heart and Renal Protection (SHARP)
was a randomized trial of simvastatin plus ezetimibe
versus placebo among 9,270 patients with CKD.11 It
is well placed to address the existing uncertainties
about the effects of smoking in patients with CKD.
More than twice as large as previous studies,12,13
SHARP has carefully phenotyped participants at
baseline, with systematic recording of smoking
quantity, prior diseases, and laboratory measure-
ments. In addition, all relevant outcomes were sys-
tematically adjudicated so that reliable information is
available for cause-speciﬁc mortality (.2,200 cases),
atherosclerotic and nonatherosclerotic vascular events
(.2,300 cases), site-speciﬁc cancer (w900 cases),
and progression of CKD (including serial creatinine
measurements and .2,100 patients reaching end-
stage renal disease [ESRD]). We therefore under-
took these analyses to investigate the relevance of
smoking to major morbidity and mortality in a large
cohort of patients with moderate to advanced CKD.
METHODS
Study Overview
From June 2003 through June 2006, a total of 9,270 participants
with CKD were enrolled into SHARP and randomly assigned to
ezetimibe/simvastatin combination therapy versus placebo.11,14
The main trial methods and results from the randomized372comparisons have been published previously.11,14 Procedures
relevant to the current analyses are summarized next. Ethics
approval was obtained from all study sites prior to enrollment.
Study Participants and Baseline Assessment
For the purpose of the current observational analyses, baseline
information refers to information that was recorded at (or in some
cases shortly before) the point at which participants were randomly
assigned to treatment with simvastatin plus ezetimibe versus pla-
cebo. Individuals 40 years or older were eligible to participate if
they were receiving maintenance dialysis or had CKD with more
than 1 previous measurement of serum or plasma creatinine of at
least 1.7 mg/dL (150 mmol/L) in men or 1.5 mg/dL (130 mmol/L)
in women. Individuals with known prior myocardial infarction,
coronary revascularization, or cancer (except for nonmelanoma
skin cancer) were excluded. All participants provided written
informed consent. Recorded baseline information included socio-
demographic characteristics (including ethnicity and highest
educational achievement), anthropometric measurements, self-
reported diagnoses of previous diseases, current medication, and
lifestyle characteristics (including alcohol consumption and
smoking status). Information for smoking status included whether
the participant was currently or had previously ever been a regular
smoker of cigarettes and, for current smokers, the number of
cigarettes smoked on a usual day. Baseline nonfasting blood and
urine samples for central laboratory measurement were also
collected. Creatinine was measured using a kinetic alkaline picrate
method, and glomerular ﬁltration rate (GFR) was estimated using
the 4-variable MDRD (Modiﬁcation of Diet in Renal Disease)
Study equation.15
Follow-up Procedures and Study Outcomes
Participants were to be seen in person at 2 months and then
every 6 months throughout the study, with additional follow-up
procedures (eg, by telephone) arranged when necessary. All par-
ticipants were to be followed up for at least 4 years. At each visit,
information for all serious adverse events (including all hospital-
izations, new diagnoses of cancer, and initiation of renal
replacement therapy) was sought and further documentation was
collected on outcomes of interest (including all vascular events,
cancer, initiation of renal replacement therapy, and all deaths).
This information was sent to the international coordinating center
for central adjudication by trained clinicians, in accordance with
prespeciﬁed deﬁnitions. For the purpose of the present analyses,
we deﬁned the following outcomes: (1) atherosclerotic vascular
event (myocardial infarction, coronary death, unstable angina,
ischemic heart failure, stroke, transient ischemic attack, arterial
revascularization, or other peripheral arterial disease event), (2)
nonatherosclerotic vascular event (other cardiac death, non-
ischemic heart failure, arrhythmia, or valvular heart disease event),
and (3) any (atherosclerotic or nonatherosclerotic) vascular event
(further details available in Item S1, provided as online supple-
mentary material). The current analyses also include analyses of
new diagnoses of cancer (excluding nonfatal nonmelanoma skin
cancers) and cause-speciﬁc mortality. Among patients not on
dialysis therapy at baseline, the main kidney disease outcomes
included progression to ESRD (ie, transplantation or initiation of
maintenance dialysis therapy) and the 2 composite outcomes of (1)
ESRD or death and (2) ESRD or doubling in creatinine level. In
addition, local hospital creatinine measurements allowed for the
estimation of each individual’s annual rate of change in estimated
GFR (eGFR) over time (as described previously).16
Statistical Analysis
The etiologic relevance of baseline smoking status (current or
former as compared to never smoker status) to particular diseasesAm J Kidney Dis. 2016;68(3):371-380
Smoking in CKDwas estimated using Cox proportional hazards regression, with the
proportional hazard assumption tested through examination of
the time dependency of the Schoenfeld partial residuals. (For all
outcomes, there was no good evidence that average relative risks
[RRs] varied with increasing follow-up.) Analyses were adjusted
for age, sex, ethnicity (white, black, Asian, and other), country,
highest educational achievement (university, secondary school,
vocational qualiﬁcation, primary school or no formal education,
and not speciﬁed), self-reported vascular disease (history of cor-
onary heart, cerebrovascular, or peripheral arterial disease), and
self-reported diabetes. Such adjustments were predicated on spe-
ciﬁc assumptions about the causal relationships between these
variables, smoking status, and outcome (Fig S1). (There were no
missing data for smoking status.) Anthropometric and biochemical
measurements (including eGFR and urine albumin-creatinine ratio
[UACR]) were not included in regression models because it was
thought that they would be unlikely to modify a person’s smoking
status (but could potentially be modiﬁed by it). In ﬁgures, the RR
(approximated by the hazard ratio [HR] estimates from the Cox
models) for each smoking group is accompanied by a group-
speciﬁc conﬁdence interval (CI) derived only from the variance
of the log risk in that one category, hence associating each RR,
including that for the reference group, with a group-speciﬁc CI that
can be thought of as reﬂecting the amount of data only in that one
category.17 Throughout the text, all quoted RRs are provided with
the CI for the comparison with the speciﬁed reference group.
Sensitivity analyses used Fine and Gray regression methods to take
account of the potential for competing risks (ie, smoking causing
death before the development of ESRD).18
RESULTS
Characteristics of Study Population by Smoking Status
At baseline, 1,243 (13%) participants were cur-
rent smokers, 3,272 (35%) were former smokers,
and 4,755 (51%) were never smokers. Of current
smokers, 475 (38%) reported smoking fewer than 10
cigarettes per day; 442 (36%), 10 to 19 cigarettes
per day; and 326 (26%), 20 or more cigarettes per
day. Median reported consumption was 10 ciga-
rettes per day. Compared with never smokers, cur-
rent smokers were younger and more likely to be
male and white (Table 1). Proportions with prior
vascular disease and in each education category in
Table 1 are no longer adjusted for age, sex and
ethnicity. Current smokers were also more likely
than never smokers to have prior vascular disease,
be a current drinker, and have lower educational
achievement. Mean blood pressures (and use of
antihypertensive treatments [Table S1]) were similar
across the smoking groups, but mean body mass
index was slightly lower in current compared with
never smokers. Proportions of participants on dial-
ysis therapy and with various underlying renal di-
agnoses were similar between the smoking groups
(except that a higher proportion of participants with
renovascular or hypertensive kidney disease were
current smokers; Table S1). Although there were no
signiﬁcant differences in eGFRs, UACRs for those
not on dialysis therapy were signiﬁcantly higher
among current smokers compared with former orAm J Kidney Dis. 2016;68(3):371-380never smokers (geometric mean UACRs of
234 6 16 [estimated standard error], 172 6 7, and
161 6 6 mg/g, respectively; P , 0.001). Among
6,245 (67%) participants not on dialysis therapy at
baseline, 88 (1%) had CKD stage 2; 2,155 (35%),
stage 3; 2,565 (41%), stage 4; and 1,219 (20%),
stage 5 at baseline (and 218 [3%] did not have a
baseline creatinine value). Of 3,025 participants on
dialysis therapy, 2,528 (84%) were receiving
maintenance hemodialysis.
Vascular Events
There were 138 (1.5%) and 204 (2.2%) partici-
pants who had less than 4 years of follow-up for
mortality and morbidity outcomes, respectively.
During a median of 4.9 years’ follow-up among
survivors, 2,317 participants had at least 1 vascular
event (annual rate, 66/1,000 patients per year), of
whom 1,406 had an atherosclerotic event (39/1,000
per year) and 1,342 had a nonatherosclerotic event
(36/1,000 per year). Compared with never smokers,
vascular event risk was 12% (adjusted HR, 1.12;
95% CI, 1.02-1.24) higher among former smokers
and 36% (adjusted HR, 1.36; 95% CI, 1.19-1.55)
higher among current smokers, respectively, the
latter reﬂecting signiﬁcant increases in both athero-
sclerotic and nonatherosclerotic events (adjusted
HRs of 1.49 [95% CI, 1.26-1.76] and 1.25 [95% CI,
1.05-1.50], respectively; Fig 1A). RRs associated
with current smoking were similar among patients
with and without a history of diabetes or vascular
disease, so that the absolute excess risks attributed to
smoking (overall, 25 [95% CI, 13-36] additional
events per 1,000 per year) were about twice as large
among those with such a history compared with
those without (36 vs 18 additional events per 1,000
per year; Fig 1B; Table S2).
Cancer
Overall, 632 participants (17/1,000 per year)
developed a new cancer (fatal or nonfatal, excluding
nonfatal nonmelanoma skin cancer) during follow-up.
Compared with never smokers, former and current
smokers had 10% (RR, 1.10; 95% CI, 0.92-1.31)
and 37% (RR, 1.37; 95% CI, 1.07-1.76) increased risk
for cancer, respectively (Fig 2A). Among current
smokers, RRs were biggest for lung cancer at 9.31
(95% CI, 4.37-19.83) and upper aerodigestive tract
cancers at 4.87 (95% CI, 2.10-11.32). Compared with
never smokers, the absolute excess of cancer was 6
(95% CI, 1-11) additional cases per 1,000 per year
(Fig 2B).
Progression of CKD
Of 6,245 participants who were not dialysis de-
pendent at baseline, 2,141 developed ESRD during373
Table 1. Baseline Demographics by Smoking Categories
Current Smoker (n 5 1,243) Former Smoker (n 5 3,272) Never Smokera (n 5 4,755) P b
Age at randomization, y 576 11 64 6 11 61 6 12 ,0.001
Male sex 900 (72%) 2,445 (75%) 2,455 (52%) ,0.001
Ethnicity ,0.001
White 925 (74%) 2,769 (85%) 2,952 (62%)
Black 58 (5%) 80 (2%) 126 (3%)
Asian 198 (16%) 330 (10%) 1,558 (33%)
Other 62 (5%) 93 (3%) 119 (3%)
Education ,0.001
University 81 (7%) 366 (11%) 615 (13%)
Secondary school 430 (35%) 1,017 (31%) 1,578 (33%)
Vocational qualifications 299 (24%) 868 (27%) 960 (20%)
Primary school or no formal education 246 (20%) 529 (16%) 950 (20%)
Not specified 187 (15%) 492 (15%) 652 (14%)
Prior vascular disease 208 (17%) 634 (19%) 551 (12%) ,0.001
Diabetes 227 (18%) 736 (22%) 1,131 (24%) ,0.001
Other baseline characteristicsc
Systolic BP, mm Hg 1406 22 139 6 22 139 6 22 0.2
Diastolic BP, mm Hg 806 12 79 6 13 79 6 13 0.001
Body mass index, kg/m2 25.7 6 5.4 27.5 6 5.5 27.2 6 5.5 ,0.001
Current drinker 29% 30% 22% ,0.001
Kidney function 0.2
eGFR, mL/min/1.73 m2d 27.36 12.9 26.6 6 13.2 26.4 6 13.1
eGFR categoryd
$60 mL/min/1.73 m2 2% 1% ,0.5%
$30-,60 mL/min/1.73 m2 23% 25% 24%
$15-,30 mL/min/1.73 m2 29% 29% 28%
,15 mL/min/1.73 m2 13% 14% 14%
Receiving dialysis 33% 31% 33%
UACRc,d
Geometric mean, mg/ge 234 6 16 172 6 7 161 6 6 ,0.001
Median, mg/g 325 [84-1,074] 171 [37-654] 207 [43-789]
UACR categoryc,d
,30 mg/g 14% 19% 22%
30-300 mg/g 36% 39% 38%
.300 mg/g 50% 41% 41%
Note: Unless otherwise indicated, values for categorical variables are given as number (percentage); values for continuous vari-
ables, as arithmetic mean 6 standard deviation or median [interquartile range].
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-creatinine ratio.
aNever regular smoker.
bP value for test of heterogeneity among the 3 smoking categories.
cAdjusted for age, sex, ethnicity, education, prior vascular disease, and prior diabetes.
dAmong those not on dialysis therapy at randomization.
eGeometric mean 6 approximate standard error.
Staplin et alfollow-up (100/1,000 per year). Compared with
never smokers, former and current smokers had a
similar rate of progression to ESRD (Fig 3). Sensi-
tivity analyses using competing-risks methodology
did not change any of the results materially (Fig S2).
Similar patterns were observed for ESRD or death
and for ESRD or doubling of serum creatinine level.
Annual rates of change in kidney function prior to
reaching ESRD among those with such assessments
over a period of at least 1 year were also similar
among current, former, and never smokers (Fig 3).
Although there was an inverse association bet-
ween baseline eGFR and rate of change in eGFR374(ie, participants starting with higher eGFRs tended
to progress more slowly), rates of change in eGFRs
(and rates of ESRD) were similar in the 3 smoking
categories at each starting eGFR (Figs S3 and S4).
This was also true at different UACRs (Figs S3 and
S4), different baseline levels of blood pressure or
antihypertensive use (Fig S5), and for different
causes of kidney disease (Fig S6). After adjustment
for age, sex, ethnicity, and baseline UACR, there
was no signiﬁcant difference in UACRs taken in
samples at 2.5 years (from participants who had
not progressed to ESRD beforehand: geometric
means of 158 [95% CI, 143-174] mg/g among neverAm J Kidney Dis. 2016;68(3):371-380
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Figure 1. Relevance of baseline smoking status to vascular outcomes, (A) overall and (B) separately by history of cardiovascular
disease (CVD) or diabetes. Relative risks are adjusted for age, sex, ethnicity, country, education, and for (A) only, prior disease (prior
CVD and diabetes) and are quoted above the squares. Numbers of events in each group are quoted below the squares. Abbreviation:
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Smoking in CKDsmokers and 166 [95% CI, 147-186] mg/g among
current smokers).
Mortality
A total of 2,257 participants died during follow-up,
including 749 from a vascular cause (19/1,000 per
year), 1,280 from a nonvascular cause (32/1,000
per year), and 228 (6/1,000 per year) from an un-
known cause. Compared with never smokers, all-cause
mortality rates were 8% (RR, 1.08; 95% CI, 0.98-
1.19) higher among former smokers and 48% (RR,
1.48 [95% CI, 1.30-1.70]; absolute excess, 28 [95%
CI, 17-38] per 1,000 per year) higher among current
smokers. Among current smokers, signiﬁcant in-
creases were seen for both vascular (RR, 1.35 [95%Am J Kidney Dis. 2016;68(3):371-380CI, 1.07-1.69]; absolute excess, 7 [95% CI, 1-13] per
1,000 per year) and nonvascular (RR, 1.60 [95% CI,
1.34-1.91]; absolute excess, 19 [95% CI, 10-27] per
1,000 per year) causes of death (Fig 4). RRs associ-
ated with smoking were similar in participants with
and without vascular disease or diabetes, but absolute
excess risks were again about twice as high among
participants with such prior disease. The increased
risk for nonvascular mortality among current smokers
chieﬂy reﬂected signiﬁcant increases in deaths due to
cancer (246 events; RR, 2.32 [95% CI, 1.58-3.40];
absolute excess, 7 [95% CI, 3-11] per 1,000 per year)
and respiratory disease (224 events; RR, 2.25 [95%
CI, 1.51-3.35]; absolute excess, 7 [95% CI, 2-11] per
1,000 per year).375
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Smoking in CKDSensitivity Analyses
RR estimates were not materially affected by addi-
tional adjustment for all baseline characteristics listed
in Table 1 (rather than only the characteristics thought
to be confounders: Fig S1), with the exception of
ESRD, for which the additional adjustment for UACR
resulted in an apparent protective association being
observed between current smoking and ESRD risk
(HR, 0.85; 95% CI, 0.74-0.98).
DISCUSSION
In this cohort of patients with CKD, smoking
increased the risk for cardiovascular disease, can-
cer, and mortality, but was not associated with
more rapid progression of kidney disease. TheseAm J Kidney Dis. 2016;68(3):371-380results are important because individuals with
CKD are already at substantially increased risk for
a wide variety of diseases, including cardiovascular
disease,8 cancer,7 progression of kidney disease,9
and death.8 Although studies in the general popu-
lation have already demonstrated that smoking in-
creases the risks for many of these (in particular
cardiovascular disease, cancer, and death2-5), pre-
vious studies of people with CKD have been much
more limited (eg, by their size and inadequate
phenotyping of outcomes: Tables S3 and S4). By
contrast, SHARP involves a large number of care-
fully adjudicated events and therefore provides a
unique opportunity to directly assess the effects
of smoking among patients with moderate to
advanced CKD.377
Staplin et alThe current study has shown that smoking increases
the risk for both atherosclerotic and nonatherosclerotic
vascular disease (the latter being the predominant
form of vascular disease in advanced CKD).19 In a
previous study of 3,941 dialysis patients, smoking was
associated with an increased risk for heart failure, but
not with an increase in risk for atherosclerotic events
(deﬁned as ischemic heart or cerebrovascular dis-
eases).10 However, unlike in SHARP, clinical out-
comes were not adjudicated and the number of
outcomes was small. In another study of 3,006 patients
with CKD, smoking was associated with an increased
risk for atherosclerotic vascular events, but the asso-
ciation with nonatherosclerotic outcomes was not re-
ported separately.13 Among studies in the general
population, 2 have reported associations between
smoking and increased risk for atherosclerotic events
among patients withmild tomoderate CKD. In theﬁrst,
among 1,249 patients with CKD (mean eGFR, 50 mL/
min/1.73 m2), the RR for current versus never smoking
was 1.82 (95% CI, 1.27-2.60).20 In the second study,
among 807 patients with eGFRs , 60 mL/min/
1.73 m2, the RR for current versus never smoking of a
major coronary event (nonfatal myocardial infarction,
coronary death, or revascularization) was 1.65 (95%
CI, 1.01-2.67).21 The observed RR for current versus
never smoking of any atherosclerotic vascular event in
SHARP was similar to these estimates, at 1.49 (95%
CI, 1.26-1.76), but somewhat less than that seen in
general studies in which the risk for myocardial
infarction is 2- to 5-fold higher among current than
never smokers.22,23 There are a number of possible
explanations for this. First, in advanced CKD (espe-
cially among patients on dialysis therapy), the diag-
nosis of myocardial infarction is complicated by
increased troponin concentrations and electrocardio-
graphic changes in the absence of acute infarction,
whichmay lead to underestimation of the magnitude of
associations.19 Second, current smokers enrolled in
SHARP had relatively low cigarette consumption
(average, 10 cigarettes per day). Third, the average age
of SHARP participants was 62 years and the RR
associated with smoking decreases with age (for
myocardial infarction, fromw6 at age 30-39 years to
2.5 at age 60-69 years).22 Finally, smoking status was
only assessed at baseline; the tendency for current
smokers to quit during follow-up would be expected to
have resulted in ﬂattening of the observed risk re-
lationships.24 These factors could also explain the
somewhat weaker associations seen for mortality in
SHARP when compared with those seen in the general
population.
Patients with CKD are at increased risk for certain
types of cancer,7,25,26 but to our knowledge, SHARP
is the ﬁrst study to investigate the effects of smoking
on site-speciﬁc cancer among patients with CKD. As378expected,2,5 the cancers most strongly associated with
smoking were lung and upper aerodigestive tract
cancers, but the observed associations were still
weaker than those seen in the general population.5
Our ﬁnding of an apparent lack of association be-
tween smoking and progression of kidney disease in a
population with CKD is in contrast to previous studies
of smoking among people with CKD (Table S4)12,13
and is surprising in view of the evidence that smok-
ing increases urinary albumin excretion27 and blood
pressure28 and has adverse effects on intrarenal he-
modynamics, particularly among patients with
CKD.29 Although the distribution of particular causes
of kidney disease in SHARP differed from those in
previous studies, we found no evidence that cause of
kidney disease signiﬁcantly modiﬁed the relationship
between smoking status and kidney disease progres-
sion (P 5 0.2; Fig S6). The reason for the discrepancy
between SHARP and other studies is therefore un-
clear, but is unlikely to be due to a lack of statistical
power; SHARP included 2,000 ESRD events (more
than all previous studies combined) and had .80%
power [at 2p50.05] to detect a RR of 1.10 for ESRD.
One difference between our analyses and those of
most previous studies is that we deliberately did not
adjust for albuminuria because we thought it would be
unlikely to inﬂuence a person’s decision to smoke (ie,
it is unlikely to be a confounder). However, urinary
albumin excretion may be modiﬁed by smok-
ing,27,30,31 in which case adjustment for it could lead
to the introduction of bias in the estimate of the as-
sociation between smoking and kidney disease pro-
gression.32 Including albuminuria in our model
creates what we believe to be an artiﬁcial association
between smoking and reduced risk for ESRD, which
is unlikely to reﬂect a true protective effect.
Our ﬁndings are of substantial public health impor-
tance because CKD and smoking are common in many
populations. In the United States, for instance, 13% of
the population is estimated to haveCKD stages 1 to 4,33
and the proportion is similar in other countries.34,35
Applying our RR estimates to national smoking prev-
alence estimates in populations with CKD,10,36,37 the
proportion of all deaths attributable to smoking would
be w6% and 7% in contemporary US and UK CKD
populations, respectively, and w9% in people with
CKD in China (where smoking is more common).
Alternatively, the RR of 1.5 for all-cause mortality
suggests that about one-third of all smokers with CKD
would be killed by their habit. As in the general pop-
ulation, the key to avoiding most of this excess risk is
likely to be cessation.2,4,38 In SHARP, the median age
at CKD diagnosis was 52 years, so cessation at diag-
nosis would likely have avoided most of the smoking-
attributable excess risk. Among smokers with CKD,
quitting would be expected to reduce mortality andAm J Kidney Dis. 2016;68(3):371-380
Smoking in CKDmorbidity more than any currently available pharma-
cologic treatment.
Although large and prospective, our analyses have
some limitations. First, we did not assess smoking
status during follow-up and therefore were unable to
adjust associations for the effects of changes in
smoking status over time. As a consequence, we may
have underestimated the strength of the association
between continuing to smoke and adverse health
outcomes.39 It also means that we were unable to
assess directly the effects of smoking cessation,
though the intermediate levels of risk observed for
former smokers in our analyses are consistent with a
strong beneﬁcial effect of cessation existing that is
similar in magnitude to that seen in other well-studied
populations.2,4,38 Second, we did not collect detailed
information about other aspects of smoking exposure
(eg, age at starting, years since quitting, types of
cigarette smoked, and inhalation behavior), somewhat
limiting the range of analyses possible. Finally, as a
special case of “collider bias,”32 it is possible that the
deliberate selection into SHARP of patients with
CKD might have created an inverse association be-
tween smoking status and other conditions (eg, car-
diovascular disease) that share risk factors with CKD,
potentially leading to a reduced association between
smoking and those conditions.
In conclusion, smoking signiﬁcantly increases the
risks for vascular and nonvascular morbidity and for
mortality in patients with CKD. For patients with
CKD who smoke, the potential beneﬁt from cessation
would be substantial and certainly much larger than
any drug treatment that is used for cardiovascular or
nephroprotection. These beneﬁts have not been
properly appreciated by nephrologists and primary
care physicians, and there is a need for smoking
cessation programs to be established as pivotal com-
ponents of the care of patients with CKD.
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